Alpha 2.0
Login Register
» Authors » Sora Paik

Sora Paik

Explore the profile of Sora Paik including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 135
Followers 0
Related Specialties
Chemistry
Biochemistry
Biology
Top 10 Co-Authors
Eun Joo Roh
Ahmed Elkamhawy
Ahmed H E Hassan
Ae Nim Pae
Kyeong Lee
Jung-Eun Park
Jong-Hyun Park
Ki Duk Park
Mohamed H Elsherbeny
Kyung-Tae Lee
Published In
Bioorg Chem
Eur J Med Chem
J Enzyme Inhib Med Chem
Eur J Pharm Sci
Pharmaceuticals (Basel)
Affiliations
Soon will be listed here.
Recent Articles
1.
Identification of Novel Aryl Carboxamide Derivatives as Death-Associated Protein Kinase 1 (DAPK1) Inhibitors with Anti-Proliferative Activities: Design, Synthesis, In Vitro, and In Silico Biological Studies
Elkamhawy A, Paik S, Ali E, Hassan A, Kang S, Lee K, et al.
Pharmaceuticals (Basel) . 2022 Sep; 15(9). PMID: 36145271
Death-associated protein kinase 1 (DAPK1) is a serine/threonine protein kinase involved in diverse fundamental cellular processes such as apoptosis and autophagy. DAPK1 isoform plays an essential role as a tumor...
2.
Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action
Elkamhawy A, Kim H, Elsherbeny M, Paik S, Park J, Gotina L, et al.
Bioorg Chem . 2021 Sep; 116:105352. PMID: 34562673
Since there is no disease-modifying treatment discovered yet for Parkinson's disease (PD), there is still a vital need to develop novel selective monoamine oxidase B (MAO-B) inhibitors as promising therapeutically...
3.
Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening
Elkamhawy A, Ammar U, Paik S, Abdellattif M, Elsherbeny M, Lee K, et al.
Molecules . 2021 Sep; 26(17). PMID: 34500757
Recently, multitargeted drugs are considered a potential approach in treating cancer. In this study, twelve in-house indole-based derivatives were preliminary evaluated for their inhibitory activities over VEGFR-2, CDK-1/cyclin B and...
4.
Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies
Elkamhawy A, Paik S, Park J, Kim H, Hassan A, Lee K, et al.
Bioorg Chem . 2021 Aug; 115:105233. PMID: 34390968
Up to date, the current clinical practice employs only symptomatic treatments for management of Parkinson's disease (PD) but unable to stop disease progression. The discovery of new chemical entities endowed...
5.
Discovery of -(1-(3-fluorobenzoyl)-1-indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B
Elkamhawy A, Paik S, Kim H, Park J, Londhe A, Lee K, et al.
J Enzyme Inhib Med Chem . 2020 Aug; 35(1):1568-1580. PMID: 32752896
Herein, two new series of -substituted indole-based analogues were rationally designed, synthesized microwave heating technology, and evaluated as noteworthy MAO-B potential inhibitors. Compared to the reported indazole-based hits and ,...
6.
Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights
Al-Sanea M, Elkamhawy A, Paik S, Lee K, El Kerdawy A, Syed Nasir Abbas B, et al.
Bioorg Med Chem . 2020 May; 28(13):115525. PMID: 32371117
Aurora kinases (AURKs) were identified as promising druggable targets for targeted cancer therapy. Aiming at the development of novel chemotype of dual AURKA/B inhibitors, herein we report the design and...
7.
Thiazolidine-2,4-dione-based irreversible allosteric IKK-β kinase inhibitors: Optimization into in vivo active anti-inflammatory agents
Elkamhawy A, Kim N, Hassan A, Park J, Paik S, Yang J, et al.
Eur J Med Chem . 2020 Jan; 188:111955. PMID: 31893550
Selective kinase inhibitors development is a cumbersome task because of ATP binding sites similarities across kinases. On contrast, irreversible allosteric covalent inhibition offers opportunity to develop novel selective kinase inhibitors....
8.
Optimization study towards more potent thiazolidine-2,4-dione IKK-β modulator: Synthesis, biological evaluation and in silico docking simulation
Elkamhawy A, Kim N, Hassan A, Park J, Yang J, Elsherbeny M, et al.
Bioorg Chem . 2019 Sep; 92:103261. PMID: 31542718
Inhibition of IKK-β (inhibitor of nuclear factor kappa-B kinase subunit beta) has been broadly documentedas a promising approach for treatment of acute and chronic inflammatory diseases, cancer, and autoimmune diseases....
9.
Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamidesAQ3 as carbonic anhydrase isoforms I and II inhibitors
Al-Sanea M, Elkamhawy A, Paik S, Bua S, Lee S, Abdelgawad M, et al.
J Enzyme Inhib Med Chem . 2019 Aug; 34(1):1457-1464. PMID: 31411080
Carbonic anhydrases (CAs, EC 4.2.1.1) are crucial metalloenzymes that are involved in diverse bioprocesses. We report the synthesis and biological evaluation of novel series of benzenesulfonamides incorporating un/substituted ethyl quinoline-3-carboxylate...
10.
EGFR inhibitors from cancer to inflammation: Discovery of 4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide as a novel anti-inflammatory EGFR inhibitor
Elkamhawy A, Hassan A, Paik S, Lee Y, Lee H, Shin J, et al.
Bioorg Chem . 2019 Jan; 86:112-118. PMID: 30685642
EGFR inhibitors are well-known as anticancer agents. Quite differently, we report our effort to develop EGFR inhibitors as anti-inflammatory agents. Pyrimidinamide EGFR inhibitors eliciting low micromolar IC and the structurally...